1. Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation
- Author
-
Giuseppe Pizzi, Adriano M. Pellicelli, Rita Golfieri, Marco Colasanti, Gianpiero D'Offizi, Raffaella Lionetti, Mario Antonini, Giovanni Vennarecci, Giovanni Battista Levi Sandri, Rosa Sciuto, Andrea Laurenzi, Roberto Santoro, Giuseppe Maria Ettorre, Pasquale Lepiane, Roberto Cianni, Roberto Luca Meniconi, and Ettorre GM, Levi Sandri GB, Laurenzi A,Colasanti M, Meniconi RL, Lionetti R, Santoro R, Lepiane P, Sciuto R, Pizzi G, Cianni R, Golfieri R, D’Offizi G, Pellicelli AM, Antonini M, Vennarecci G
- Subjects
Adult ,Male ,medicine.medical_specialty ,Liver Transplantation Tace Barcelona Clinic Liver Cancer Milan Criterion Microvascular Invasion ,Carcinoma, Hepatocellular ,medicine.medical_treatment ,Liver transplantation ,Milan criteria ,Preoperative care ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Preoperative Care ,Carcinoma ,Medicine ,Humans ,Yttrium Radioisotopes ,Survival analysis ,Aged ,Retrospective Studies ,business.industry ,Liver Neoplasms ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Embolization, Therapeutic ,Liver Transplantation ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,030211 gastroenterology & hepatology ,Female ,Surgery ,Radiopharmaceuticals ,business ,Abdominal surgery - Abstract
BACKGROUND: Liver transplantation (LT) is a well-established procedure for hepatocellular carcinoma (HCC) within the Milan criteria. Yttrium-90 microspheres radioembolization (Y90-RE) has shown to be an effective and safe treatment of primary liver tumors. We retrospectively evaluate the efficacy of the Y90-RE in patients with HCC prior to LT. METHODS: From January 2002 to December 2015, 365 patients were transplanted at the San Camillo Hospital Center. One hundred forty-three patients were transplanted for HCC, and in 22 cases the patients were treated with Y90-RE before LT. RESULTS: Three patients were treated with Y90-RE within the Milan criteria, and 19 patients were out of criteria before Y90-RE. Four patients had an increasing MELD score between Y90-RE and LT. On the other hand, alpha-fetoprotein decreases after Y90-RE treatment in all cases. No patient death was observed in Y90-RE procedure or at LT. In 78.9 % of cases, a successful downstaging was observed, and in 100 % of cases bridging was achieved. From Y90-RE treatment overall survival was 43.9 months. From LT, overall mean survival was 30.2 months with a free survival of 29.6 months. The overall survival after LT analysis between the patients treated with Y90-RE and patients without was not significant (p = 0.113). Free survival analysis was not significant (p = 0.897) between the two populations. CONCLUSIONS: We successfully performed LT in patients after Y90-RE treatment both as bridging and downstaging for HCC and obtained a similar overall and free survival of LT for HCC within Milan criteria. Y90-RE becomes a real option to provide curative therapy for patients who traditionally are not considered eligible for surgery.
- Published
- 2017